Adaptimmune Therapeutics plc ADAPY
0.03 USD 0.00 (+21.95%)
Nov 3, 2026, 3:59 PM EST
0.0176 Day range 0.0266
0.001 52-week range 0.07
- YTD
- -3.85%
- 1 year
- -44.44%
- Market cap
- 6.63M
- EPS (ttm)
- -0.67
- YTD return
- -3.85%
- 1-year return
- -44.44%
- Volume
- 235.91K
- Avg volume
- 191.08K
- Open
- 0.0176
- Previous close
- 0.0205
- Day's range
- 0.0176 – 0.0266
- 52-week range
- 0.001 – 0.07
5D +0.0027 (+10.76%)
Financials — quick view
ADAPY Revenue — quarterly 13.68M
ADAPY Net income — quarterly -30.34M
ADAPY EPS — quarterly -0.12
News
Adaptimmune Announces Changes to Board and Executive Leadership Team 
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP 
Adaptimmune Announces Delisting from Nasdaq 
Adaptimmune Reports Q2 Financial Results and Provides Business Update 
Adaptimmune Announces Entry into Definitive Agreement for Sale of TECELRA, lete-cel, afami-cel and uza-cel Cell Therapies to US WorldMeds 
Adaptimmune Therapeutics plc (ADAP) Q1 2025 Earnings Call Transcript 
Adaptimmune Reports Q1 Financial Results and Provides Business Update 
Adaptimmune to Report Q1 2025 Financial and Business Updates on Tuesday, May 13, 2025 
Adaptimmune Therapeutics plc (ADAP) Q4 2024 Earnings Call Transcript 
Adaptimmune Provides Q4 and Full Year 2024 Business Update
Your note
Sign in to keep a note on ADAPY — it syncs with the Stock Master app.